Pathophysiology of Cardio-Renal Interactions
|
|
- Noah Jordan
- 5 years ago
- Views:
Transcription
1 European Society of Cardiology 2011 Paris-France Pathophysiology of Cardio-Renal Interactions Claudio Ronco, MD Department of Nephrology St. Bortolo Hospital International Renal Research Institute Vicenza - Italy
2 DECLARATION OF CONFLICT OF INTEREST Speaker honoraria from Abbott Alere Gambro
3 Pathophysiology of Cardio-Renal Interactions Heart-Kidney Interactions: Bidirectional Temporally regulated Mediated by different mechanisms Different consequences in specific individuals Functional vs structural damage They may affect other organs Cardio Renal Syndrome and its consequences The importance of an early diagnosis
4 Cardio-Renal Interactions Basically a vicious circle Primary Insult Primary Insult ADHF - CHF AKI - CKD AKI-CKD Physiological derangements ADHF-CHF Physiological derangements Renal dysfunction Heart dysfunction
5 Acute ADHF leading to AKI Cardiac Surgery Cardiac procedures CIN CPB Valve replacement Cardio-Renal Chronic HF (systolic or diastolic) leading to : CKD CKD progression Diuretic resistant oliguria Chronic Acute Kidney Injury leading to AHF Volume/uremiainduced ADHF Renal ischemiainduced ADHF Sepsis/cytokine induced AKI and HF Reno-Cardiac CKD increasing cardiovascular mortality CKD increasing cardiovascular morbidity Chronic HF progression due to CKD Uremia related HF Volume related HF
6 Cardio-Renal syndromes General Definition: Pathophysiologic disorder of the heart and kidneys whereby acute or chronic dysfunction in one organ induces acute or chronic dysfunction in the other CRS Type I (Acute Cardiorenal Syndrome) Abrupt worsening of cardiac function leading to acute kidney injury CRS Type II (Chronic Cardiorenal Syndrome) Chronic abnormalities in cardiac function causing progressive and permanent chronic kidney disease CRS Type III (Acute Renocardiac Syndrome) Abrupt worsening of renal function causing acute cardiac disorders CRS Type IV (Chronic Renocardiac Syndrome) Chronic kidney disease contributing to decreased cardiac function, cardiac hypertrophy and/or increased risk of adverse cardiovascular events CRS Type V (Secondary Cardiorenal Syndrome) Systemic condition (e.g. diabetes mellitus, sepsis) causing both cardiac and renal dysfunction
7 A widely accepted classification
8 CRS Type 1 CRS Type 2 AKI CKD Markers of Damage NGAL, Cystatin C, KIM 1 Markers of Function BUN, Creatinine, GFR/eGFR
9 Cardio-Renal Syndrome Type 1 Hemodynamically mediated damage Decreased CO Exogenous Factors Contrast media ACE inhibitors Diuretics Decreased perfusion Toxicity Vascocostriction. Increased venous pressure Acute Heart Disease Acute decompensation Ischemic insult Coronary angiography Cardiac surgery Humoral signalling BNP Sympathetic Activation Neuro-mediated damage RAA activation, Na + H2O retention, vasoconstriction Hormonal factors Immune mediated damage Natriuresis Cytokine secretion Acute Kidney Injury Renal hypoperfusion Reduced oxygen delivery Necrosis / apoptosis Decreased GFR Resistance to ANP/BNP Caspase activation Apoptosis Monocyte Activation Endothelial activation Caspase activation Apoptosis
10 Cardio-Renal Syndrome Type 1 LCOS and Congestion Acute Heart Disease Acute Kidney Injury Upon initial recognition, AKI induced by primary cardiac dysfunction implies inadequate renal perfusion until proven otherwise. This should prompt clinicians to consider the diagnosis of a low cardiac output state (LCOS) and/or marked increase in venous pressure leading to kidney congestion. It is important to remember that central venous pressure translated to the renal veins is a product of right heart function, blood volume, and venous capacitance which is largely regulated by neuro-hormonal systems. Specific regulatory and counter-regulatory mechanisms are activated with variable effects depending on the duration and the intensity of the insult.
11 RAA SYSTEM ANP - BNP SYMPATHETIC NS VASOPRESSIN
12 Cardio-Renal Syndrome Type 1 Hemodynamic mechanisms Vasocostriction Decreased cardiac output Arterial underfilling Functional (Pre-renal) Diseased heart Compensatory Mechanisms Decreased perfusion pressure A K I Increased preload Vasoconstriction Vasodilatation Parenchymal Venous congestion Increased venous pressure
13 Cardio-Renal Syndrome Type 1 Compensatory mechanisms in HF Natriuresis Afterload Vasocostriction Sympathetic Nervous System R-A-A System Arginin Vasopressin Endothelin Water excretion Sodium excretion Urea readsorption HF Compensatory Mechanisms Natriuresis Afterload Natriuretic Peptides Chinin-kallicrein System Prostaglandins Endothelial Relaxin Factor Vasodilatation Water excretion Sodium excretion Urea readsorption
14 AVP in normal and failing heart Normal Heart AVP Sympathetic tone decrease Vasodilat. RAA Water excretion Sodium excretion INCREASED ATRIAL PRESSURE BNP Non-osmotic AVP release Arterial underfilling V 1a -mediated vasocostriction AVP V 2 receptors RAA Water excretion Failing Heart BNP Sodium excretion Urea readsorption
15 Time windows for AKI management Fluids Drugs Nephroprotection? Diuretics RRT
16 RIFLE max and AKI outcomes 1,0,8,6,4 Non ARD Risk Injury Failure,2 0,0 0 P<0.001 (Log Rank) Days after Length hospital of hospital admission stay (d) Hoste et al. Crit Care. 2006;10(3):R73
17 Biology of AKI by Time-Zones BIOMARKERS Multiple Timezone Organ Damage Clock Display MOLECULAR CELLULAR BIOMARKER CLINICAL
18 Clinical Continuum of AKI Devarajan, Biomarkers Med 4:265-80, 2010
19 Structural AKI Biomarkers Early diagnosis of evolving AKI could result in prevention and/or earlier changes in management: Prevention of disease progression either stopping harmful interventions or mitigating/avoiding exposure to the insult Early therapeutic interventions designed to protect the kidney More accurate differential diagnosis of AKI could direct appropriate therapy of AKI (pre-renal vs renal) More accurate staging of AKI could help prognostic stratification and therapy of AKI Serial staging of phases of AKI (evolution of the syndrome) Assessment of current and future severity of injury
20 AKI Biomarkers McIlroy et al, Anesthesiology 2010; 112:
21 Cardio-Renal Syndrome Type 1 Hemodynamically mediated damage Decreased CO Decreased perfusion Increased venous pressure Acute Heart Disease Humoral signalling BNP Diuretics & UF Sympathetic Activation Humorally mediated damage RAA activation, Na + H2O retention, vasoconstriction Hormonal factors Immune mediated damage Toxicity Vascocostriction. Natriuresis Cytokine secretion Acute Kidney Injury Renal hypoperfusion Reduced oxygen delivery Necrosis / apoptosis Decreased GFR Resistance to ANP/BNP Caspase activation Apoptosis Monocyte Activation Endothelial activation Caspase activation Apoptosis
22 Time Course of worsening of renal function (Creatinine increase) in hospitalized HF patients Gotlieb et Al, JACC 2008 DIURETICS
23 Management with the Five B Balance & BW Blood Pressure Biomarkers Bioimpedance Blood Volume
24 Creatinine Day 0 Diuretics Day 1 Day2 Day 3 Day 4 Day BNP Diuresis
25 2000 Stop Diuretics «5B» NGAL Warning Creatinine Day 0 Diuretics Day 1 Day2 Day 3 Day 4 Day 5 NGAL BNP Diuresis
26 Transcellular water flux Osmolality Interstitium Intravascular Refilling Starling Forces Cardiovascular Conditions Vascular Space Blood Volume Extracorporeal Uf
27 R e l a t i v e C h a n g e s Blood Pressure Blood Volume Uf / Refilling rate related hypotension a Overall ECFV related hypotension a 1 UF beginning UF end
28 THE PATHWAY FOR FLUID BALANCE The 5 B approach Blood Pressure Drugs & SCUF Blood Volume BIOMARKERS B.I.V.A. HEART KIDNEY Body Weight - BALANCE
29 Cardio-Renal Syndrome Type 1 Hemodynamically mediated damage Decreased CO Decreased perfusion Increased venous pressure Acute Heart Disease Humoral signalling BNP Exogenous factors Contrast media ACE inhibitors Diuretics Sympathetic Activation Humorally mediated damage RAA activation, Na + H2O retention, vasoconstriction Hormonal factors Immuno mediated damage Toxicity Vascocostriction. Natriuresis Cytokine secretion Acute Kidney Injury Renal hypoperfusion Reduced oxygen delivery Necrosis / apoptosis Decreased GFR Resistance to ANP/BNP Caspase activation Apoptosis Monocyte Activation Endothelial activation Caspase activation Apoptosis INFLAMMATION
30 Current issues in AKI management
31 APOPTOSIS STUDY IN CRS Type 1 Patient Table 1. Baseline characteristics of CRS Type 1 patients and clinical parameters Sex Age (years) CKD Stage Cause of CKD Creatinine at enrollment (mg/dl) Urea at enrollment (mg/dl) AKI N stage at enrol lmen t RRT Prior MI or revascularization Prior history of cardiac disease 1 M 83 V Uncertain Yes Yes ICM 2 M 80 III DM No No AF 3 M 71 V DM Yes No No 4 M 28 V HTN No No No 5 M 81 II DM Yes No No 6 M 71 III DM Yes No ICM 7 M 85 IV Uncertain Yes No No 8 F 60 IV HTN No No AF 9 M 85 V Uncertain Yes Yes ICM 10 M 48 IV DM Yes No AF 11 F 84 III DM No No No 12 M 67 IV DM Yes Yes ICM 13 F 82 IV Uncertain Yes Yes ICM, HTN HD 14 F 80 IV HTN No No DCM 15 M 88 III DM No Yes ICM
32 APOPTOSIS STUDY IN CRS T.1 and CONTROLS Plasma-induced apoptosis after 72h (%) Plasma-induced apoptosis after 96h (%) CRS Type 1 patients Healthy controls (n=15) (n=20) p-value 78 (52.0 to 93.0) 11 (10.0 to 12.5) < (62.0 to 92.0) 11 (10.5 to 13.0) <0.001 Caspase-8 (S/B ratio) 0.91 (0.75 to 1.02) 0.44 (0.41 to 0.52) 0.01 Evaluation of apoptosis and Caspase-8 activity in U937 cells after incubation with plasma from CRS Type 1 patients and healthy volunteers. Results (median, interquartile range) are given as percentage of apoptotic cells/field for apoptosis at 72h and 96h or signal to background (S/B) ratio for Caspase-8 activity at 24h
33 Percentage of Apoptosis APOPTOSIS STUDY IN CRS T.1 and CONTROLS Evaluation of percentage of apoptosis in U937 cells after incubation with plasma from CRS Type 1 patients and healthy volunteers for 72h and 96h CTR 72h CRS Type1 72h CTR 96h CRS Type1 96h
34 Cardio-Renal Syndrome Type 1 Inflammation/humoral theory Cytokines Supernatant R T C Colture Plasma Monocyte Cell Colture Apoptosis Apoptosis
35 APOPTOSIS STUDY IN HEART FAILURE Evaluation of percentage of apoptosis in U937 cells after incubation with plasma from Heart Failure Patients developing CRS Type 1 (HF/AKI) or not (HF/No AKI) MW CTR 1B 2B 1A 2A 100,0% 80,0% p=0.008 p=0.006 p=0.006 p= ,0% 47,6% 51,4% 47,0% 58,8% 40,0% 28,0% 30,8% 36,8% 20,0% 16,5% 0,0% 24h 48h 72h 96h HF/No AKI HF/AKI n.6 n.6
36 Cardiorenal Syndrome Patient Subsets Low EF High CVP Low CO/CI Poor perfusion Poor Renal Perfusion 20% Fixed CKD 20% egfr < 60 DM HTN Intercurrent event/procedure Neurohumoral Decomp 60% Baseline egfr ~75 ml/min Set off by IV diuresis ( RAAS, SNS) Initially BP Other drug insults (Na, NSAIDS, TZD s, others) Intercurrent event/procedure McCullough, ACC 2006
37 Cardiorenal Syndrome Patient Subsets De Novo HF 15% 25% ACS and cardiogenic shock 60% ADHF on Established HF ADQI,2008
38 Cardio-Renal Syndrome Type 1 Acute Heart Disease Acute Kidney Injury Occurs in ~25% of unselected patients admitted with ADHF. Among these patients, pre-morbid CKD is common and predisposes to AKI in approximately 60% of cases. AKI is an independent risk factor for 1-year mortality in ADHF patients including in patients with ST-elevation myocardial infarction who develop signs and symptoms of heart failure or have a reduced left ventricular ejection fraction. This independent effect might be due to an associated acceleration in cardiovascular pathobiology due to kidney dysfunction through the activation of neurohormonal, cell signaling, oxidative stress, or exuberated repair (fibrosis) pathways.
39 Cardio-Renal Syndrome: possible pathophysiological mechanisms of AKI following HF Hemodynamic deterioration (congestion, CO, perfusion) Myocardial damage injury HF progression Renal dysfunction (AKI) Neurohormonal & cytokine activation Gheorghiade M et al. Am J Cardiol. 2005
40 Cardiorenal Syndrome Risk Factors Characteristics Adjusted OR 95% CI P Value Women 1.41 ( ).003 HTN 1.64 ( ).003 Rales>Bases 1.28 ( ).03 HR >100 bpm 1.34 ( ).01 SCr 1.5 mg/dl 1.77 ( ) <.001 SBP >200 mm Hg 1.63 ( ).009 N=1,681 Krumholz HM et al. Am J Cardiol. 2000;85:1110.
41 Obesity and cardiometabolic changes Diabetes Sleep Apnea Heart Disease G.I. Tract Disorders Obesity Kidney Disease High Blood Pressure TNF-a IL-6 F F A Inflammation CRP Atherosclerosis Coronary artery disease Cardiac remodelling LVH-Dilatation Lean adipose tissue Obese adipose tissue Crosstalk Leptin Resistin Adiponectin Apoptosis Dysmetabolic syndrome Chronic ischemia CKD Fibrosissclerosis
42 CARDIO-RENAL CACHEXIA SYNDROMES Non-oedematous weight loss of >6% of total body weight over a period of 6 or more months CRS TYPES 1-2 CRS TYPES 3-4 Low Cardiac output Na and fluid overload Chronic hypoperfusion Embolism Venous Congestion Chronic inflammation Cardiac Remodeling Endothelial Dysfunction Acceler. Atherosclerosis Na and fluid overload Chronic inflammation Uremic Toxins Malnutrition Anemia EPO resistance ph abnormalities Ca-P abmormalities Lack of VDR activation Soft Tissue calcifications Malnutrition, loss of >10% of lean tissue or percent of ideal weight <90%. CKD Progression, Apoptosis Necrosis, Fibrosis, Sclerosis Heart Failure, Systolic/diastolic dysfunction, Myoc.Remodelling
43 AKI Cardio-Renal Syndrome Anemia and Iron deficiency Reduced Blood Viscosity Decreased Oxygen Delivery Increased Sympathetic Activity Hyperdynamic circulation CKD Cardiac Work Cardiac Output Arterial diameter and volume Arterial wall tension Left ventricle hypertrophy Left Ventricle wall tension Eccentric remodelling of the arterial system AKI CKD Left ventricle eccentric remodelling
44 Cardio-Renal Syndrome CKD and UREMIA CKD + HD CVR CKD = CVR b * f ( + X) HD techno/dr
45 Cardio-Renal Syndrome CKD and UREMIA CKD Glomerular- -interstitial damage Sclerosis - Fibrosis Acquired Risk factors Primary nephropathy Anemia Uremic toxins Ca/P abnormalities Nutritional status, BMI Na H 2 O overload Chronic Inflammation Anemia & malnutrition Ca/P abnormalities Na H 2 O overload Unfriendly milieu Inflammation CHF
46 Cardio-Renal Syndrome The unfriendly uremic milieu Uremia retention products Bone remodeling Insulin resistance Muscle catabolism Acute phase reactants Fetuin-A Adipocytokine production Appetite REE Endothelial dysfunction Monocyte adhesion Smooth muscle cell proliferation LDL oxidation Vascular calcification Oxidant stress
47 Risk of Cardiorenal Syndrome (%) Risk of Cardiorenal Syndrome by Number of Risk Factors 6,0 5,0 4,0 3,0 2,0 1,0 16% 24% 29% 38% 53% 0, No. of Risk Factors Krumholz HM et al. Am J Cardiol. 2000;85:1110.
48 CONCLUSIONS Heart-kidney interactions are bidirectional, time-dependent, and the are mediated by several pathophysiological mechanisms PHYSICAL CHEMICAL BIOLOGICAL Pre existing or concomitant pathological conditions represent important risk factors for developing CRS
49 CONCLUSIONS Recognize patient subsets and risk factors Consider biomarkers for early identification Understand precipitating factors Medications Procedures Explore new avenues for CRS prevention and organ protection based on pathophysiological mechanisms
Pathophysiology of Cardio-Renal Interactions
Pathophysiology of Cardio-Renal Interactions Claudio Ronco, MD Department of Nephrology St. Bortolo Hospital International Renal Research Institute Vicenza - Italy Pathophysiology of Cardio-Renal Interactions
More informationDoppler ultrasound, see Ultrasonography. Magnetic resonance imaging (MRI), kidney oxygenation assessment 75
Subject Index Acidemia, cardiorenal syndrome type 3 146 Acute Dialysis Quality Initiative (ADQI) acute kidney injury biomarkers, see Acute kidney injury; specific biomarkers cardiorenal syndrome, see specific
More informationTHE KIDNEY IN HYPOTENSIVE STATES. Benita S. Padilla, M.D.
THE KIDNEY IN HYPOTENSIVE STATES Benita S. Padilla, M.D. Objectives To discuss what happens when the kidney encounters low perfusion To discuss new developments and clinical application points in two scenarios
More informationCardiorenal Syndrome
Cardiorenal Syndrome Peenida Skulratanasak, M.D. Division of Nephrology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University Definition of Cardiorenal syndrome (CRS) Structural
More informationHeart Failure and Cardio-Renal Syndrome 1: Pathophysiology. Biomarkers of Renal Injury and Dysfunction
CRRT 2011 San Diego, CA 22-25 February 2011 Heart Failure and Cardio-Renal Syndrome 1: Pathophysiology Biomarkers of Renal Injury and Dysfunction Dinna Cruz, M.D., M.P.H. Department of Nephrology San Bortolo
More informationLe sindromi cardio renali G. VESCOVO
Le sindromi cardio renali G. VESCOVO G. VESCOVO MD, PhD, FESC Dip. Medicina Interna VICENZA Le sindromi cardio renali Consensus Conference Prevalence of CVD Any CVD: 80 million (1 in 3) Htn: 73 million
More informationCardiorenal Syndrome
SOCIEDAD ARGENTINA DE CARDIOLOGIA Cardiorenal Syndrome Joint session ESC-SAC ESC Congress 2012, Munich César A. Belziti Hospital Italiano de Buenos Aires I have no conflicts of interest to declare Cardiorenal
More informationCardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology
Cardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology Heart and Kidney The kidney yin dominates water, The heart yang
More informationNovel Approaches for Recognition and Management of Life Threatening Complications of AKI and CKD: Focus on Acute Cardiorenal Syndromes
Novel Approaches for Recognition and Management of Life Threatening Complications of AKI and CKD: Focus on Acute Cardiorenal Syndromes Peter A. McCullough, MD, MPH Baylor University Medical Center, Dallas
More informationThe Cardiorenal Syndrome in Heart Failure
The Cardiorenal Syndrome in Heart Failure Van N Selby, MD Assistant Professor of Medicine Advanced Heart Failure Program, UCSF October 9, 2015 Disclosures None 1 Cardiorenal Syndrome (CRS) A pathophysiologic
More informationHeart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA
Heart Failure and Renal Failure Gerasimos Filippatos, MD, FESC, FHFA President HFA Definition Epidemiology Pathophysiology Management (?) Recommendations for NHLBI in cardiorenal interactions related to
More informationPivotal Role of Renal Function in Acute Heart failure
Pivotal Role of Renal Function in Acute Heart failure Doron Aronson MD, FESC Department of Cardiology RAMBAM Health Care Campus Haifa, Israel Classification and definitions of cardiorenal syndromes CRS
More informationOvercoming the Cardiorenal Syndrome
Overcoming the Cardiorenal Syndrome October 29, 2016 Randall C Starling MD MPH FACC FESC FHFSA FHFA Professor of Medicine Heart & Vascular Institute Cleveland Clinic Lerner College of Medicine Cleveland
More informationThe Triple Threat. Cardiac Care in the NT Annual Workshop 2017 is proudly supported by:
The Triple Threat DR KELUM PRIYADARSHANA FRACP CONSULTANT NEPHROLOGIST ROYAL DARWIN HOSPITAL Cardiac Care in the NT Annual Workshop 2017 is proudly supported by: Pathogenesis Diabetes CKD CVD Diabetic
More informationCardiorenal and Renocardiac Syndrome
And Renocardiac Syndrome A Vicious Cycle Cardiorenal and Renocardiac Syndrome Type 1 (acute) Acute HF results in acute kidney injury Type 2 Chronic cardiac dysfunction (eg, chronic HF) causes progressive
More informationCardiorenal syndrome. Sofie Gevaert. Ghent University Hospital, Belgium
Cardiorenal syndrome Sofie Gevaert Ghent University Hospital, Belgium Disclosures Consultancy Astra Zeneca Boegringer MSD Novartis 68 y old man, ADHF ICMP, ejection fraction 35 %: progressive dyspnea,
More informationHeart Failure and Renal Disease Cardiorenal Syndrome
Advanced Heart Failure: Clinical Challenges Heart Failure and Renal Disease Cardiorenal Syndrome 17 th Apr 2015 Ju-Hee Lee, M.D Cardiovascular Center, Chungbuk National University Hospital Chungbuk National
More informationState of the Art: acute heart failure Is it just congestion?
ESC CONGRESS 2017 Barcelona, 26. 30. August 2017 State of the Art: acute heart failure Is it just congestion? S.B. Felix, FESC Klinik für Innere Medizin B Ernst-Moritz-Arndt-Universität Greifswald 1456
More informationUnderstanding the Cardio-Renal Syndromes
Understanding the Cardio-Renal Syndromes The Cardio-Renal axis: an underestimated player in cardiovascular diseases ESC Congress Munich 27/08/2012 Alberto Palazzuoli Department of Internal Medicine Cardiology
More informationBiomarkers, the Kidney and the Heart: Acute Kidney Injury
Biomarkers, the Kidney and the Heart: Acute Kidney Injury 12th Annual Conference on Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices San Diego May 13, 2016 Ravindra
More informationTreating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment
ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University
More informationRuolo dei Marcatori Bioumorali nello scompenso cardiaco
Ruolo dei Marcatori Bioumorali nello scompenso cardiaco Head Emergency Medicine Sant Andrea Hospital Director Postgraduate School of Emergency Medicine Faculty od Medicine and Psycology Sapienza University
More informationFluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI)
Fluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI) Robert W. Schrier, MD University of Colorado School of Medicine Denver, Colorado USA Prevalence of acute renal failure in Intensive
More informationPathophysiology: Heart Failure
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Medicine Outline Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology Heart Failure: Definitions
More informationCopyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Normal Cardiac Anatomy
Mosby,, an affiliate of Elsevier Normal Cardiac Anatomy Impaired cardiac pumping Results in vasoconstriction & fluid retention Characterized by ventricular dysfunction, reduced exercise tolerance, diminished
More informationMedical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011
Medical Treatment for acute Decompensated Heart Failure Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 2010 HFSA guidelines for ADHF 2009 focused update of the 2005 American College
More informationCardio-Renal Syndrome in Acute Heart Failure:
Cardio-Renal Syndrome in Acute Heart Failure: Target for Therapy Marvin A. Konstam, M.D. Research support and/or consulting relevant to this lecture: Merck, Otsuka, Johnson & Johnson; Amgen; Cardiokine
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationPearls in Acute Heart Failure Management
Pearls in Acute Heart Failure Management Best Practices Juan M. Aranda Jr., M.D. Professor of Medicine Medical Director of Heart Failure/ Transplant Program University of Florida College of Medicine Disclosures:
More informationOutline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies
Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the
More informationRecognizing and Treating Patients with the Cardio-Renal Syndrome
Recognizing and Treating Patients with the Cardio-Renal Syndrome Joachim H. Ix, MD, MAS, FASN Professor of Medicine Chief; Division of Nephrology-Hypertension University of California San Diego 1 Conflicts
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationCirculation. Blood Pressure and Antihypertensive Medications. Venous Return. Arterial flow. Regulation of Cardiac Output.
Circulation Blood Pressure and Antihypertensive Medications Two systems Pulmonary (low pressure) Systemic (high pressure) Aorta 120 mmhg Large arteries 110 mmhg Arterioles 40 mmhg Arteriolar capillaries
More informationΟξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών;
Οξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών; Γ. Φιλιππάτος, MD, FACC, FESC, FCCP Επ. Καθηγητής Καρδιολογίας Πανεπ. Αθηνών Clinical Outcomes in Patients
More informationAcute Kidney Injury for the General Surgeon
Acute Kidney Injury for the General Surgeon UCSF Postgraduate Course in General Surgery Maui, HI March 20, 2011 Epidemiology & Definition Pathophysiology Clinical Studies Management Summary Hobart W. Harris,
More informationEditorial Staying in the Pink of Health for Patients with Cardiorenal Anemia Requires a Multidisciplinary Approach
Editorial Staying in the Pink of Health for Patients with Cardiorenal Anemia Requires a Multidisciplinary Approach Anemia and Heart Failure Ragavendra R. Baliga, MD, MBA James B. Young, MD Consulting Editors
More informationObjectives 6/14/2016. Cardiorenal Syndrome: Critical Link Between Heart and Kidney
Cardiorenal Syndrome: Critical Link Between Heart and Kidney Chris M. Bell, ACNP Cardiology Associates of North Mississippi Objectives Review the 5 Subtypes of the Cardiorenal Syndrome (CRS) Discuss the
More informationUpdate on Cardiorenal Syndrome: A Clinical Conundrum
Advances in Peritoneal Dialysis, Vol. 27, 2011 Eric J. Chan, 1 Kevin C. Dellsperger 1 3 Update on Cardiorenal Syndrome: A Clinical Conundrum Our understanding of the cardiorenal syndrome continues to progress.
More informationCardiorenal Biomarkers and Heart Failure. Nicholas Wettersten, MD April 7 th, 2017
Cardiorenal Biomarkers and Heart Failure Nicholas Wettersten, MD April 7 th, 2017 Disclosures Still none, but looking for some Acute Kidney Injury Biomarkers 547 in 2015 4112 as of March 2017 Case 1 60
More informationThe right heart: the Cinderella of heart failure
The right heart: the Cinderella of heart failure Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland none Disclosure Look into the Heart
More informationPathophysiology: Heart Failure. Objectives
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Clinical Medicine Objectives At the conclusion of this seminar, learner will be able to: 1. Define heart failure as a clinical
More informationHeart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output
Cardiac Anatomy Heart Failure Professor Qing ZHANG Department of Cardiology, West China Hospital www.blaufuss.org Cardiac Cycle/Hemodynamics Functions of the Heart Essential functions of the heart to cover
More informationManagement of Advanced Systolic Heart Failure. Robert W. Hull MD FACC Associate Professor of Medicine West Virginia University
Management of Advanced Systolic Heart Failure Robert W. Hull MD FACC Associate Professor of Medicine West Virginia University American College of Cardiology Foundation (ACCF) American Heart Association
More informationMedical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Medical Management of Acutely Decompensated Heart Failure William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Goals of Acute Heart Failure Therapy Alleviate
More informationAcute heart failure syndromes: clinical challenges. Pathophysiology. ESC Congress August. Paris, France. Marco Metra
ESC Congress 2011 27-31 August. Paris, France. Acute heart failure syndromes: clinical challenges. Pathophysiology Marco Metra Cardiology, Dept. Of experimental and applied medicine. University of Brescia.
More informationThe Art and Science of Diuretic therapy
The Art and Science of Diuretic therapy Dr. Fayez EL Shaer Associate Professour of cardiology Consultant cardiologist MD, MSc, PhD, CBNC, NBE FESC, ACCP, FASNC,HFA KKUH, KFCC Heart failure: fluid overload
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationNT-proBNP: Evidence-based application in primary care
NT-proBNP: Evidence-based application in primary care Associate Professor Rob Doughty The University of Auckland, Auckland City Hospital, Auckland Heart Group NT-proBNP: Evidence in Primary Care The problem
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationCardio Renal Disease. Dr. Rajasekara Chakravarthi Head, Dept of Nephrology CARE Hospitals Hyderabad
Cardio Renal Disease Dr. Rajasekara Chakravarthi Head, Dept of Nephrology CARE Hospitals Hyderabad PREVALENCE OF CVD IS HIGH CAD LVH CHF (CLINICAL) (ECHO) (CLINICAL) GENERAL POPULATION 5-12% 20% 5% CKD
More informationThe Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?
The Who, How and When of Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center Lebanon, NH May 20, 2013 Joseph G. Rogers,
More informationBiomarkers in cardiovascular disease. Felix J. Rogers, DO, FACOI April 29, 2018
Biomarkers in cardiovascular disease Felix J. Rogers, DO, FACOI April 29, 2018 Biomarkers NIH: A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological
More informationIntravenous Inotropic Support an Overview
Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)
More informationCase Presentation. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.
Worsening Renal Function in Heart Failure Patients Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationHeart-failure or Kidney Failure?
Heart-failure or Kidney Failure? Dr Ajith James Consultant Nephrologist Barts Health and BHRUT Mr AR 65 yrs Case Type 2 DM, IHD-MI 1998, 2003. PCI x 3. CABG 2008, HT CCF with LVEF 30% 2014. NYHA Class
More informationUsing Lung Ultrasound to Diagnose and Manage Acute Heart Failure
Using Lung Ultrasound to Diagnose and Manage Acute Heart Failure Jennifer Martindale, MD Assistant Professor Department of Emergency Medicine SUNY Downstate/Kings County Hospital Brooklyn, NY What is acute
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationJOSHUA K. KAYIMA INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY
INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY JOSHUA K. KAYIMA ASSOCIATE PROFESSOR DEPT. OF CLINICAL MEDICINE AND THERAPEUTICS UNIVERSITY OF NAIROBI Introduction According to
More informationContrast Induced Nephropathy
Contrast Induced Nephropathy O CIAKI refers to an abrupt deterioration in renal function associated with the administration of iodinated contrast media O CIAKI is characterized by an acute (within 48 hours)
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More informationNGAL Connect to the kidneys
NGAL Connect to the kidneys Acute kidney injury (AKI) An imposing medical and diagnostic challenge >13 million AKI patients each year ~ 30% with fatal outcome Cardiac surgery > 1 million patients/year
More informationHEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
HEART FAILURE PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the effects of heart failure in the body
More informationPathophysiology: Heart Failure. Objectives
Pathophysiology: Heart Failure Mat Maurer, MD Associate Professor of Clinical Medicine Objectives At the conclusion of this seminar, learners will be able to: 1. Define heart failure as a clinical syndrome
More informationPre-discussion questions
Amanda Bartlett, PA-C Dustin Bartlett, PA-C Andrea Applegate, PA-C Leslie Yearta Brown, NP CHF Round Table Discussion Objectives ANDREA- Discuss the definition and different categories of CHF DUSTIN- Define
More informationDuring exercise the heart rate is 190 bpm and the stroke volume is 115 ml/beat. What is the cardiac output?
The Cardiovascular System Part III: Heart Outline of class lecture After studying part I of this chapter you should be able to: 1. Be able to calculate cardiac output (CO) be able to define heart rate
More informationSAFETY IN THE CATH LAB How to Minimise Contrast Toxicity
SAFETY IN THE CATH LAB How to Minimise Contrast Toxicity Dr. Vijay Kunadian MBBS, MD, MRCP Senior Lecturer and Consultant Interventional Cardiologist Institute of Cellular Medicine, Faculty of Medical
More informationRRT in Advanced Heart Failure and Liver Failure When to start and when to stop?
Critical Care Medicine Apollo Hospitals RRT in Advanced Heart Failure and Liver Failure When to start and when to stop? Ramesh Venkataraman, AB (Int. Med), AB (CCM) Senior Consultant, Critical Care Medicine
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ. ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Ά ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Διευθυντής: Καθηγητής Δημήτριος Τούσουλης ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
More informationΟξεία Καρδιακή Ανεπάρκεια: Κλινική εικόνα, ταξινόμηση κινδύνου & προγνωστικοί δείκτες
Οξεία Καρδιακή Ανεπάρκεια: Κλινική εικόνα, ταξινόμηση κινδύνου & προγνωστικοί δείκτες Στράτος Θεοφιλογιαννάκος, MD, PhD Ιατρείο Καρδιακής Ανεπάρκειας, Γ Πανεπιστημιακή Καρδιολογική Κλινική ΑΠΘ, ΠΓΝ Ιπποκράτειο
More informationHeart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France
Heart Failure Guillaume Jondeau Hôpital Bichat, Paris, France Epidemiology Importance of PEF Europe I-PREFER study. Abstract: 2835 Prevalence of HF Preserved LV systolic Function older (65 vs 62 y, p
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationProf. Andrzej Wiecek Department of Nephrology, Endocrinology and Metabolic Diseases Medical University of Silesia Katowice, Poland.
What could be the role of renal denervation in chronic kidney disease? Andrzej Wiecek, Katowice, Poland Chairs: Peter J. Blankestijn, Utrecht, The Netherlands Jonathan Moss, Glasgow, UK Prof. Andrzej Wiecek
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationBlood Pressure Regulation 2. Faisal I. Mohammed, MD,PhD
Blood Pressure Regulation 2 Faisal I. Mohammed, MD,PhD 1 Objectives Outline the intermediate term and long term regulators of ABP. Describe the role of Epinephrine, Antidiuretic hormone (ADH), Renin-Angiotensin-Aldosterone
More informationBlood Pressure Regulation 2. Faisal I. Mohammed, MD,PhD
Blood Pressure Regulation 2 Faisal I. Mohammed, MD,PhD 1 Objectives Outline the intermediate term and long term regulators of ABP. Describe the role of Epinephrine, Antidiuretic hormone (ADH), Renin-Angiotensin-Aldosterone
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationPractical Points in Cardiorenal Syndrome
Practical Points in Cardiorenal Syndrome Vichai Senthong, MD. Cardiovascular Unit, Faculty of Medicine Khon Kaen university HFCT Annual Scientific Meeting June 16, 2017, Eastin Grand Sathorn Hotel, Bangkok
More informationCardiovascular Complications Of Chronic Kidney Disease. Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen
Cardiovascular Complications Of Chronic Kidney Disease Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen Markers of kidney dysfunction Raised Albumin / Creatinine
More informationDiastolic Heart Failure. Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012
Diastolic Heart Failure Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012 Disclosures Have spoken for Merck, Sharpe and Dohme Sat on a physician advisory
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationOlistic Approach to Treatment Adequacy in AKI
Toronto - Canada, 2014 Olistic Approach to Treatment Adequacy in AKI Claudio Ronco, MD Department of Nephrology, St. Bortolo Hospital, International Renal Research Institute Vicenza - Italy 1) RRT
More informationHyponatremia as a Cardiovascular Biomarker
Hyponatremia as a Cardiovascular Biomarker Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu Disclosure Research grant from Otsuka for the
More informationCardio-renal syndrome.
Review Article Cardio-renal syndrome. http://www.alliedacademies.org/archives-of-general-internal-medicine/ ISSN: 2591-7951 Dhiraj Kumar*, Abhijeet Yelale, Girish Sabnis, Hetan Shah, Charan Lanjewar, Prafulla
More informationDr.Nahid Osman Ahmed 1
1 ILOS By the end of the lecture you should be able to Identify : Functions of the kidney and nephrons Signs and symptoms of AKI Risk factors to AKI Treatment alternatives 2 Acute kidney injury (AKI),
More informationDietary practices in patients with chronic kidney disease not yet on maintenance dialysis: What are the relevant components?
Dietary practices in patients with chronic kidney disease not yet on maintenance dialysis: What are the relevant components? 3 rd International Conference of European Renal Nutrition Working Group of ERA-EDTA
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationFOCUS ON CARDIOVASCULAR DISEASE
The Consequences of Vitamin D Deficiency: FOCUS ON CARDIOVASCULAR DISEASE Vitamin D deficiency is a global health problem. With all the medical advances of the century, vitamin D deficiency is still epidemic.
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationDefining and Managing the Cardiorenal Syndrome in Acute Decompensated Heart Failure. Barry M. Massie Professor of Medicine UCSF
Defining and Managing the Cardiorenal Syndrome in Acute Decompensated Heart Failure Barry M. Massie Professor of Medicine UCSF DISCLOSURES Consulting fees: Merck-Novacardia Novartis Bristol Myers Squibb
More informationBiomarkers for optimal management of heart failure. Cardiorenal syndrome. Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland
Biomarkers for optimal management of heart failure Cardiorenal syndrome Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland Presenter Disclosure Information V-P Harjola The following
More informationCopeptin in heart failure: Associations with clinical characteristics and prognosis
Copeptin in heart failure: Associations with clinical characteristics and prognosis D. Berliner, N. Deubner, W. Fenske, S. Brenner, G. Güder, B. Allolio, R. Jahns, G. Ertl, CE. Angermann, S. Störk for
More informationCardiorenal Syndrome: What the Clinician Needs to Know. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Cardiorenal Syndrome: What the Clinician Needs to Know William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Renal Hemodynamics in Heart Failure Glomerular
More informationMcHenry Western Lake County EMS System Paramedic, EMT-B and PHRN Optional Continuing Education 2018 #12 Understanding Preload and Afterload
McHenry Western Lake County EMS System Paramedic, EMT-B and PHRN Optional Continuing Education 2018 #12 Understanding Preload and Afterload Cardiac output (CO) represents the volume of blood that is delivered
More informationAcute Kidney Injury after Cardiac Surgery: Incidence, Risk Factors and Prevention
Acute Kidney Injury after Cardiac Surgery: Incidence, Risk Factors and Prevention Hong Liu, MD Professor of Clinical Anesthesiology Department of Anesthesiology and Pain Medicine University of California
More information